Olivier Raymond Brandicourt's most recent trade in BeiGene Ltd - ADR was a trade of 34,151 Share Option (Right to Buy) done . Disclosure was reported to the exchange on June 5, 2024.
Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
---|---|---|---|---|---|---|---|---|---|---|
BeiGene Ltd - ADR | Olivier Raymond Brandicourt | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 34,151 | 34,151 | - | - | Share Option (Right to Buy) | |
BeiGene Ltd - ADR | Olivier Raymond Brandicourt | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 16,341 | 16,341 (0%) | 0% | 0 | Ordinary Shares | |
Alnylam Pharmaceuticals Inc | Olivier Raymond Brandicourt | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 May 2024 | 5,228 | 5,228 | - | - | Stock Option (right to buy) | |
BeiGene Ltd - ADR | Olivier Raymond Brandicourt | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Feb 2024 | 27,794 | 27,794 | - | - | Share Option (Right to Buy) | |
Alnylam Pharmaceuticals Inc | Olivier Raymond Brandicourt | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2023 | 3,454 | 3,454 | - | - | Stock Option (right to buy) | |
Alnylam Pharmaceuticals Inc | Olivier Raymond Brandicourt | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2022 | 5,153 | 5,153 | - | - | Stock Option (right to buy) | |
Alnylam Pharmaceuticals Inc | Olivier Raymond Brandicourt | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jul 2021 | 4,032 | 4,032 | - | - | Stock Option (right to buy) |